US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus LifeSci Biotech Products ETF

108.63

+1.271.18%

Volume:10K

Turnover:1.08M

Market Cap:119.50M

PE:- -

High:109.80

Open:109.80

Low:107.84

Close:107.37

52wk High:110.05

52wk Low:68.05

Shares:1.10M

Float Shares:1.10M

Volume Ratio:1.70

T/O Rate:0.91%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Bio-Gene Technology to Hold Virtual Extraordinary General Meeting in August

How FDA Priority Review for First-in-Class LGMD Drug BBP-418 Could Impact BridgeBio Pharma (BBIO) Investors

Simply Wall St.

Analyst Lifts BridgeBio Price Target to $98 as BBP‑418 Becomes Core Growth Driver Following Strong Phase 3 Data

BridgeBio Wins FDA Priority Review for BBP-418 Therapy

BridgeBio announces FDA acceptance, priority review of BBP-418 NDA

BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

BridgeBio submits BBP-418 NDA to FDA

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BBP/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Products ETF","latestPrice":108.634,"timestamp":1788371150217,"preClose":107.3666,"halted":0,"volume":9965,"delay":0,"changeRate":0.011804415898426466,"floatShares":1100004,"shares":1100004,"eps":0,"marketStatus":"Trading","change":1.2674,"latestTime":"09-02 13:45:54 EDT","open":109.7996,"high":109.7996,"low":107.8399,"amount":1078281.7585,"amplitude":0.018252,"askPrice":108.74,"askSize":8,"bidPrice":108.37,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":107.3666,"sharesOutstanding":600004,"nav":106.153,"aum":116768523.01,"bidAskSpread":0.002387,"postHourTrading":{"tag":"盘后","latestPrice":106.97,"preClose":107.3666,"latestTime":"19:30 EDT","volume":9,"amount":966.2928,"timestamp":1788305405531,"change":-0.3966,"changeRate":-0.003694,"amplitude":0},"volumeRatio":1.704052,"impliedVol":0.2303,"impliedVolPercentile":0.5119},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","floatShares":1100004,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.704052,"shares":1100004,"dividePrice":0,"high":109.7996,"amplitude":0.018252,"preClose":107.3666,"low":107.8399,"week52Low":68.046,"pbRate":"--","week52High":110.05,"institutionHeld":0,"latestPrice":108.634,"committee":0.851852,"eps":0,"divideRate":0,"volume":9965,"delay":0,"ttmEps":0,"open":109.7996,"prevYearClose":79.9149,"prevWeekClose":105.9199,"prevMonthClose":106.46,"prevQuarterClose":96.2686,"fiveDayClose":108.6574,"twentyDayClose":96.8774,"sixtyDayClose":84.0972},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBP\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649596643","title":"Bio-Gene Technology to Hold Virtual Extraordinary General Meeting in August","url":"https://stock-news.laohu8.com/highlight/detail?id=2649596643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649596643?lang=en_us&edition=fundamental","pubTime":"2026-07-06 12:57","pubTimestamp":1783313831,"startTime":"0","endTime":"0","summary":"Bio-Gene Technology Ltd. ( ($AU:BGT) ) has shared an announcement. Bio-Gene Technology Ltd., the ASX-listed biotechnology company, is convening an ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bio-gene-technology-to-hold-virtual-extraordinary-general-meeting-in-august?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bio-gene-technology-to-hold-virtual-extraordinary-general-meeting-in-august?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","AGNG","XT","BK4588","DARP","FHLC","RSPH","SYNB","BK4585","JDOC","FWD","BGT","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641161303","title":"How FDA Priority Review for First-in-Class LGMD Drug BBP-418 Could Impact BridgeBio Pharma (BBIO) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641161303","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641161303?lang=en_us&edition=fundamental","pubTime":"2026-06-05 01:20","pubTimestamp":1780593617,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma announced that the FDA previously accepted and granted Priority Review to its New Drug Application for oral BBP-418 in LGMD2I/R9, setting a PDUFA target action date of November 27, 2026, without planning an advisory committee meeting.\nIf approved, BBP-418 would be the first therapy for LGMD2I/R9 and any limb-girdle muscular dystrophy, potentially qualifying BridgeBio for a Priority Review Voucher and opening up further rare disease development paths.\nWe’ll now examine how...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/how-fda-priority-review-for-first-in-class-lgmd-drug-bbp-418","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/how-fda-priority-review-for-first-in-class-lgmd-drug-bbp-418","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","BK4505","BK4211","BK4139","BK4585","ISBC","BBP","BK4588","BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638001639","title":"Analyst Lifts BridgeBio Price Target to $98 as BBP‑418 Becomes Core Growth Driver Following Strong Phase 3 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2638001639","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638001639?lang=en_us&edition=fundamental","pubTime":"2026-05-28 05:16","pubTimestamp":1779916591,"startTime":"0","endTime":"0","summary":"In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on BridgeBio Pharma, with a price target of $98.00. Sean Laaman...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-lifts-bridgebio-price-target-to-98-as-bbp418-becomes-core-growth-driver-following-strong-phase-3-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-lifts-bridgebio-price-target-to-98-as-bbp418-becomes-core-growth-driver-following-strong-phase-3-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638639953","title":"BridgeBio Wins FDA Priority Review for BBP-418 Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2638639953","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638639953?lang=en_us&edition=fundamental","pubTime":"2026-05-28 05:00","pubTimestamp":1779915620,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma ( ($BBIO) ) just unveiled an update. On May 27, 2026, BridgeBio Pharma announced that the U.S. Food and Drug Administration accept...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bridgebio-wins-fda-priority-review-for-bbp-418-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bridgebio-wins-fda-priority-review-for-bbp-418-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","LABU","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638915500","title":"BridgeBio announces FDA acceptance, priority review of BBP-418 NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2638915500","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638915500?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:17","pubTimestamp":1779884262,"startTime":"0","endTime":"0","summary":"BridgeBio (BBIO) announced the FDA has accepted for filing its new drug application, or NDA, with Priority Review for oral BBP-418 for the treatmen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bridgebio-announces-fda-acceptance-priority-review-of-bbp-418-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bridgebio-announces-fda-acceptance-priority-review-of-bbp-418-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBP","BK4505","LABU","BK4139","BK4585","BK4588","BBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638021595","title":"BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9","url":"https://stock-news.laohu8.com/highlight/detail?id=2638021595","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638021595?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:30","pubTimestamp":1779881400,"startTime":"0","endTime":"0","summary":"- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for tr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301817/0/en/BridgeBio-Announces-FDA-Acceptance-and-Priority-Review-of-NDA-for-BBP-418-for-LGMD2I-R9.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4081","BBP","LABU","EMA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623762312","title":"BridgeBio submits BBP-418 NDA to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2623762312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623762312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:56","pubTimestamp":1774871788,"startTime":"0","endTime":"0","summary":"BridgeBio (BBIO) announced the submission of its new drug application to the FDA for oral BBP-418 for the treatment of individuals living with limb...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bridgebio-submits-bbp-418-nda-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bridgebio-submits-bbp-418-nda-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBP","BK4505","LABU","BBIO","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623916312","title":"BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9","url":"https://stock-news.laohu8.com/highlight/detail?id=2623916312","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623916312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870200,"startTime":"0","endTime":"0","summary":"- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264527/0/en/BridgeBio-Submits-NDA-to-FDA-for-BBP-418-for-Individuals-Living-with-LGMD2I-R9.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","LABU","BK4081","BK4585","BK4588","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618274899","title":"BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9","url":"https://stock-news.laohu8.com/highlight/detail?id=2618274899","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618274899?lang=en_us&edition=fundamental","pubTime":"2026-03-12 02:00","pubTimestamp":1773252000,"startTime":"0","endTime":"0","summary":"- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentationat MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified su","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/11/3254081/0/en/BBP-418-Demonstrates-Consistent-Efficacy-and-Favorable-Safety-Profile-in-Phase-3-FORTIFY-Interim-Analysis-in-LGMD2I-R9.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FVC","BBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":7,"totalSize":129,"code":"91000000","status":"200"}]}}